Peripheral Biomarkers RFP supports researchers and clinicians developing and validating peripheral biomarkers to advance drug development for Alzheimer's disease and related dementias.
Funder: Alzheimer's Drug Discovery Foundation
Due Dates: Due Dates (Anticipated): Not yet announced
Funding Amounts: Exploratory: generally up to approximately $250,000; proof-of-principle: generally up to $500,000; validation: based on stage and scope
Summary: Supports peripheral biomarker development and validation to advance drug development for Alzheimer's disease and related dementias.
Key Information: For-profit companies receive mission-related investments requiring a return on investment.
The Alzheimer's Drug Discovery Foundation's Diagnostics Accelerator supports peripheral biomarkers that advance drug development for Alzheimer's disease and related dementias. The program encourages blood, saliva, urine, and ocular biomarkers with a rational biological connection to disease processes. It covers diagnostic, monitoring, predictive, prognostic, pharmacodynamic/response, safety, and susceptibility/risk biomarkers.
Research priorities include vascular injury and blood-brain barrier integrity, neuroinflammation, neuroprotection and neurodegeneration, frontotemporal degeneration, protein misfolding, synaptic integrity or activity, and mitochondrial and metabolic function. Other approaches supported by compelling biological evidence are encouraged. Supported work ranges from pilot studies through larger clinical validation studies, with emphasis on reliable assays, reproducibility, well-characterized samples, and a path toward commercialization. Development of CSF and neuroimaging biomarkers is excluded, although these tools may validate peripheral biomarkers.